REGENXBIO Financial Statements (RGNX)
|
|
|
|
Report date
|
|
|
31.12.2022 |
28.02.2023 |
27.02.2024 |
13.03.2025 |
05.03.2026 |
|
05.03.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
112.7 |
112.7 |
90.2 |
83.3 |
170.4 |
|
170.4 |
|
Operating Income, bln rub |
|
|
-262.9 |
-262.9 |
-268.1 |
-233.3 |
-161.2 |
|
-161.2 |
|
EBITDA, bln rub |
? |
|
-257.0 |
-244.2 |
-239.5 |
-198.2 |
-145.6 |
|
-145.6 |
|
Net profit, bln rub |
? |
|
-280.3 |
-280.3 |
-263.5 |
-227.1 |
-193.9 |
|
-193.9 |
|
|
OCF, bln rub |
? |
|
|
-207.5 |
-218.4 |
-173.1 |
-124.0 |
|
-124.0 |
|
CAPEX, bln rub |
? |
|
|
30.7 |
9.96 |
2.44 |
2.41 |
|
2.41 |
|
FCF, bln rub |
? |
|
|
-238.2 |
-228.4 |
-175.6 |
-126.4 |
|
-126.4 |
|
Dividend payout, bln rub
|
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
375.6 |
321.1 |
321.2 |
283.1 |
311.3 |
|
251.3 |
|
Cost of production, bln rub |
|
|
54.5 |
54.5 |
37.2 |
33.6 |
20.3 |
|
80.3 |
|
R&D, bln rub |
|
|
242.5 |
242.5 |
232.3 |
208.5 |
228.3 |
|
224.4 |
|
Interest expenses, bln rub |
|
|
23.3 |
23.3 |
6.86 |
12.7 |
45.0 |
|
45.0 |
|
|
Assets, bln rub |
|
|
833.3 |
833.3 |
574.0 |
466.0 |
453.0 |
|
453.0 |
|
Net Assets, bln rub |
? |
|
516.2 |
516.2 |
311.7 |
259.7 |
102.7 |
|
102.7 |
|
Debt, bln rub |
|
|
94.8 |
94.8 |
89.3 |
82.0 |
260.5 |
|
260.5 |
|
Cash, bln rub |
|
|
364.6 |
364.6 |
275.3 |
234.7 |
230.1 |
|
230.1 |
|
Net debt, bln rub |
|
|
-269.8 |
-269.8 |
-186.0 |
-152.7 |
30.4 |
|
30.4 |
|
|
Ordinary share price, rub |
|
|
22.7 |
22.7 |
18.0 |
7.73 |
14.4 |
|
10.2 |
|
Number of ordinary shares, mln |
|
|
43.2 |
43.2 |
43.7 |
49.5 |
51.6 |
|
51.8 |
|
|
Market cap, bln rub |
|
|
979 |
979 |
785 |
383 |
743 |
|
530 |
|
EV, bln rub |
? |
|
709 |
709 |
599 |
230 |
773 |
|
560 |
|
Book value, bln rub |
|
|
516 |
516 |
312 |
260 |
103 |
|
103 |
|
|
EPS, rub |
? |
|
-6.50 |
-6.50 |
-6.02 |
-4.59 |
-3.76 |
|
-3.75 |
|
FCF/share, rub |
|
|
0.00 |
-5.52 |
-5.22 |
-3.55 |
-2.45 |
|
-2.44 |
|
BV/share, rub |
|
|
12.0 |
12.0 |
7.13 |
5.24 |
1.99 |
|
1.99 |
|
|
EBITDA margin, % |
? |
|
-228.0% |
-216.7% |
-265.4% |
-237.9% |
-85.4% |
|
-85.4% |
|
Net margin, % |
? |
|
-248.7% |
-248.7% |
-292.0% |
-272.5% |
-113.8% |
|
-113.8% |
|
FCF yield, % |
? |
|
0.00% |
-24.3% |
-29.1% |
-45.9% |
-17.0% |
|
-23.9% |
|
ROE, % |
? |
|
-54.3% |
-54.3% |
-84.5% |
-87.5% |
-188.7% |
|
-188.7% |
|
ROA, % |
? |
|
-33.6% |
-33.6% |
-45.9% |
-48.7% |
-42.8% |
|
-42.8% |
|
|
P/E |
? |
|
-3.49 |
-3.49 |
-2.98 |
-1.69 |
-3.83 |
|
-2.73 |
|
P/FCF |
|
|
|
-4.11 |
-3.44 |
-2.18 |
-5.88 |
|
-4.19 |
|
P/S |
? |
|
8.68 |
8.68 |
8.70 |
4.59 |
4.36 |
|
3.11 |
|
P/BV |
? |
|
1.90 |
1.90 |
2.52 |
1.47 |
7.23 |
|
5.16 |
|
EV/EBITDA |
? |
|
-2.76 |
-2.90 |
-2.50 |
-1.16 |
-5.31 |
|
-3.85 |
|
Debt/EBITDA |
|
|
1.05 |
1.10 |
0.78 |
0.77 |
-0.21 |
|
-0.21 |
|
|
R&D/CAPEX, % |
|
|
|
789.1% |
2 332% |
8 560% |
9 457% |
|
9 296% |
|
|
CAPEX/Revenue, % |
|
|
0.00% |
27.3% |
11.0% |
2.92% |
1.42% |
|
1.42% |
|
| REGENXBIO shareholders |
